Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Clover Health Investments

Hippo Holdings

iShares U.S. Insurance ETF

Invesco KBW Property & Casualty Insurance ETF

SPDR S&P Insurance ETF

Lemonade

Root

Insurance technology companies were some of the best performing US insurers on Wall Street over the course of 2024, while the managed care sector had a less resilient year. Root Inc., Clover Health Investments Corp., Hippo Holdings Inc. and Lemonade Inc. were the top four performers for insurers with a market cap greater than $300 million for the year.

Insurtechs Shine On Wall Street In 2024 As Managed Care Struggles

LOUISVILLE, Ky.--(BUSINESS WIRE)--Leading health and well-being company Humana Inc. (NYSE: HUM) announced today that it has named Japan Mehta as Chief Information Officer. In this role, Mehta will oversee Humana's digital and technology organization, as well as its data systems. He will also set the technology transformation vision for the company to better connect consumers to their caregivers and enable better clinical decision making, while also driving greater efficiencies through technolog.

Humana Names Japan Mehta as Chief Information Officer

BRYAN-COLLEGE STATION, Texas--(BUSINESS WIRE)--Texas A&M University-Mays Business School and Humana announce winners of 8th annual Healthcare Analytics Case Competition.

Texas A&M University-Mays Business School and Humana Announce Winners of Eighth Annual Healthcare Analytics Case Competition

Cigna

The healthcare industry, particularly PBMs, faces bipartisan scrutiny, leading to significant stock declines for Humana and Cigna, presenting a contrarian investment opportunity. President-elect Donald Trump's stance on PBMs and bipartisan legislative proposals signal potential regulatory changes, creating market uncertainty for PBM-affiliated companies. Despite recent financial setbacks, Cigna and Humana show strong revenue growth, with investment losses and rising benefit costs impacting short-term profitability.

Humana, Cigna Plunge On Trump's Latest Promise: A Potential Buying Opportunity?

CVS Health

UnitedHealth Group

Centene

Elevance Health Inc

Shares of major healthcare companies fell nearly 5% on Wednesday on concerns related to potential changes to their complex business models. That includes UnitedHealth Group, Cigna and CVS Health, which operate three of the nation's largest private health insurers and drug supply chain middlemen called pharmacy benefit managers.

Health care stocks fall as lawmakers, patients push for changes to their business models

Shares of health insurers such as UnitedHealth and CVS Health fell on Wednesday after a Wall Street Journal report said a bipartisan group of lawmakers were set to introduce legislation to break up pharmacy-benefit managers.

Health insurer stocks fall as WSJ says lawmakers set to break up pharmacy-benefit managers

Archer-Daniels-Midland Company

Automatic Data Processing

Ares Capital

Atmos Energy

Broadcom

American Express

Bank of America

British American Tobacco

Celanese

Carlisle Companies

Cintas Corp

Coterra Energy

Dick's Sporting Goods

Dow Inc

Enbridge

EOG Resources

Gaming and Leisure Properties

Huntington Ingalls Industries

Johnson & Johnson

Lennar

Lam Research

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields about 3.28%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 9%.

5 Relatively Secure And Cheap Dividend Stocks For December 2024: Yields Up To 9%

Shares of UnitedHealthcare's parent company led a broader selloff in health insurance stocks, losses one analyst described as a likely result of the industry's fresh focus following the Wednesday killing of UnitedHealthcare's chief executive Brian Thompson.

Health Insurance Stocks—Led By UnitedHealth—Suffer Steep Drops Following Brian Thompson's Killing

Humana's stock has declined 18% while the S&P 500 returned 13.5%, driven by short-term issues with Medicare Advantage. Despite short-term cost challenges, Medicare Advantage remains a long-term tailwind, and CenterWell coordinated care isn't priced into Humana's strategy. I maintain buy rating at a price target of $370, 28% upside.

Humana: Medicare Advantage Is Just A Short-Term Problem

OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--AM Best has downgraded the Financial Strength Rating (FSR) to B+ (Good) from B++ (Good) and the Long-Term Issuer Credit Rating (Long-Term ICR) to “bbb-” (Good) from “bbb” (Good) of Humana Insurance of Puerto Rico, Inc. and Humana Health Plans of Puerto Rico, Inc. These companies are domiciled in Puerto Rico and collectively are referred to as Humana Health of Puerto Rico Group. The outlook of these Credit Ratings (ratings) has been revised to negative from stable.

AM Best Downgrades Credit Ratings of Humana Health of Puerto Rico Group's Subsidiaries; Affirms Credit Ratings of Humana Inc. and Most of Its Health Insurance Subsidiaries

Humana Inc said on Tuesday that Chief Financial Officer Susan Diamond was stepping down and Celeste Mellet would replace her, effective Jan. 11.

Humana says Susan Diamond to step down as CFO

LOUISVILLE, Ky.--(BUSINESS WIRE)--Leading health and well-being company Humana Inc. (NYSE: HUM) announced today that Celeste Mellet will be appointed to succeed Susan Diamond as Chief Financial Officer (CFO), effective January 11, 2025. Diamond is stepping down after a successful 18-year career at Humana, including over three years as CFO, and will serve in an advisory role through the end of 2025 to ensure a smooth transition. “On behalf of the entire Board and management team, I want to exten.

Humana Announces CFO Transition

Humana (HUM) reported earnings 30 days ago. What's next for the stock?

Humana (HUM) Up 15.1% Since Last Earnings Report: Can It Continue?

NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM

LOUISVILLE, Ky.--(BUSINESS WIRE)--Leading health and well-being company Humana Inc. (NYSE: HUM) announced today that it has named Michelle O'Hara as Chief Human Resources Officer, effective January 1, 2025. O'Hara will oversee the enterprise talent strategy and people programs for Humana's more than 63,000 employees. She brings a proven track record of transforming HR capabilities and enabling companies to effectively attract, recruit, develop and retain a talented and diverse workforce. O'Hara.

Humana Appoints Michelle O'Hara as Chief Human Resources Officer

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Recognized for Commitment to Veteran Employment by Military Times and Military Friendly®.

Humana Recognized for Commitment to Veteran Employment by Military Times and Military Friendly®

Shares of Humana Inc (NYSE:HUM) are down 3.7% at $277.38 at last glance, after Cigna Group (NYSE:CI) said it was not pursuing a merger with the smaller health insurance name, and will instead prioritize share buybacks.

2 Healthcare Stocks in Focus After Merger Talks Break Down

Humana (HUM) shares are falling 5% in premarket trading Monday after The Cigna Group (CI) said it is not pursuing a combination with its smaller health insurance rival.

Humana Stock Slumps as Cigna Says It's Not Pursuing Combination

US health insurer Cigna has made the appropriate decision to ditch plans to merge with rival Humana (NYSE:HUM), if today's market reaction is anything to go by. Rumours of the merger, which would have created a $140 billion insurance behemoth, began circulating last December, but doubts over the deal quickly followed.

Cigna rallies after Humana mega-merger called off

Investors have long appeared skeptical about a potential merger between the two health insurers.

Humana Stock Tumbles. Cigna Won't Pursue the Health Insurer.

Health insurer Cigna Group said on Monday it is not pursuing a combination with peer Humana.

Cigna says it will not pursue combination with Humana

Molina Healthcare

Several US health insurers saw notable stock price gains following the reelection of former US President Donald Trump amid an expectation of less federal scrutiny. Humana Inc. experienced the largest increase as its stock rose 10.7% from Nov. 1 through Nov. 6, increasing from $260.71 a share to $288.51 a share.

Trump Win Gives Some U.S. Health Insurers A Post-Election Bump On Wall Street

WASHINGTON--(BUSINESS WIRE)--Humana and Evolent expand their partnership to enhance oncology care and help drive better patient outcomes.

Humana and Evolent Expand Partnership to Enhance Oncology Care

BioNTech SE

HCA Healthcare

Eli Lilly

Pfizer

Tenet Healthcare

Universal Health Services

Health Care Select Sector SPDR Fund

Investors are worried about what a Trump administration means for hospital operators and vaccine makers, but are optimistic about the fate of Medicare Advantage plan providers.

Why most healthcare stocks are falling with Trump's win, with some exceptions

Humana's stock has fallen over 30% due to rising healthcare utilization and CMS pushing back on insurer profits, impacting MA-focused companies. Despite headwinds, Humana's Q3 earnings showed resilience with adjusted EPS of $4.16 and upgraded individual MA membership growth by 40k members. Humana aims for a 3% margin by 2027, focusing on clinical excellence, efficient operations, and strategic growth, while navigating CMS challenges and potential M&A opportunities.

News for Humana Stock (HUM)